Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
National Institute of Mental Health (NIMH) |
---|---|
Information provided by: | National Institutes of Health Clinical Center (CC) |
ClinicalTrials.gov Identifier: | NCT00407576 |
Alzheimer's disease is associated with accumulation in the brain of a protein called amyloid. The purpose of this study is to test the ability of a research drug to measure amyloid in brain using positron emission tomography (PET) and a research drug called [11C]MeS-IMPY.
Condition | Intervention |
---|---|
Alzheimer's Disease Healthy |
Drug: [11C]MeS-IMPY |
Study Type: | Interventional |
Study Design: | Treatment |
Official Title: | PET Imaging of Brain Amyloid Using [11C]MeS-IMPY |
Estimated Enrollment: | 30 |
Study Start Date: | December 2006 |
Estimated Study Completion Date: | November 2008 |
Alzheimer's disease (AD) is characterized pathologically by the presence of beta-amyloid plaques in brain. A substantial body of research indicates that the presence of increased beta -amyloid peptide is neurotoxic, and may initiate further pathology observed in AD including neurofibrillary tangles, synaptic loss and dysfunction, and neurodegeneration. There are multiple binding sites available on beta-amyloid plaques. Three clearly identified sites are Congo-red type, Thioflavin-T type, and FDDNP type. Radioligands currently under development using positron emission tomography (PET) for studying beta-amyloid in clinical research or drug development are based on Thioflavin-T site, such as [11C]PIB and [11C]SB-13. Though variously effective, these radioligands have one or more drawbacks with respect to measuring relative regional beta-amyloid densities. Therefore, we have recently developed [11C]MeS-IMPY as an alternative radioligand for imaging beta-amyloid, which will allow a more accurate quantification of amyloid plaques in AD brain. In the current protocol, we wish to evaluate [11C]MeS-IMPY in both healthy subjects and AD patients to determine the kinetics of brain imaging beta-amyloid plaques in AD patients.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Healthy control subjects aged 18-90 years and AD patients aged 50-90, with history/physical exam, ECG, and laboratory tests.
Informed Consent.
AD Patients: Mini-Mental State Examination (score greater than or equal to 10).
AD Patients: Meet NINCDS-ADRDA criteria for probable AD.
EXCLUSION CRITERIA:
Study ID Numbers: | 070036, 07-M-0036 |
Study First Received: | December 2, 2006 |
Last Updated: | November 8, 2008 |
ClinicalTrials.gov Identifier: | NCT00407576 |
Health Authority: | United States: Federal Government |
Alzheimer's Disease Positron Emission Tomography Brain Neurochemistry Beta-Amyloid Plaques PET |
MeS-IMPY Alzheimer Disease AD Dementia Healthy Volunteer HV |
Delirium, Dementia, Amnestic, Cognitive Disorders Mental Disorders Alzheimer Disease Central Nervous System Diseases Healthy Neurodegenerative Diseases |
Brain Diseases Dementia 2,3-dihydro-1H-imidazo(1,2-b)pyrazole Cognition Disorders Delirium |
Antineoplastic Agents Therapeutic Uses Nervous System Diseases Tauopathies Pharmacologic Actions |